{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:13:15Z","timestamp":1774437195895,"version":"3.50.1"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2013,5,31]],"date-time":"2013-05-31T00:00:00Z","timestamp":1369958400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0065719","type":"journal-article","created":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T04:43:35Z","timestamp":1370061815000},"page":"e65719","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Determination of Olanzapine and N-desmethyl-olanzapine in Plasma Using a Reversed-Phase HPLC Coupled with Coulochemical Detection: Correlation of Olanzapine or N-desmethyl-olanzapine Concentration with Metabolic Parameters"],"prefix":"10.1371","volume":"8","author":[{"given":"Mong-Liang","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Hui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Chuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huai-Chih","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-Hua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,5,31]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Bymaster F, Perry KW, Nelson DL, Wong DT, Rasmussen K, <etal>et al<\/etal>.. (1999) Olanzapine: a basic science update. Br J Psychiatry Suppl: 36\u201340.","DOI":"10.1192\/S0007125000293653"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","article-title":"Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial","volume":"14","author":"CM Beasley Jr","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, <etal>et al<\/etal>.. (2010) Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev: CD006654.","DOI":"10.1002\/14651858.CD006654.pub2"},{"key":"ref4","first-page":"177","article-title":"Olanzapine. Pharmacokinetic and pharmacodynamic profile","volume":"37","author":"JT Callaghan","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/00007691-200208000-00010","article-title":"Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting","volume":"24","author":"E Skogh","year":"2002","journal-title":"Ther Drug Monit"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.pnpbp.2008.08.022","article-title":"Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors","volume":"32","author":"TH Wu","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00228-006-0209-9","article-title":"The effect of variable cigarette consumption on the interaction with clozapine and olanzapine","volume":"62","author":"T Haslemo","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"742","DOI":"10.4088\/JCP.v61n1006","article-title":"Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses","volume":"61","author":"KI Melkersson","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/01.ftd.0000249950.75462.7f","article-title":"Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication","volume":"28","author":"FM Theisen","year":"2006","journal-title":"Ther Drug Monit"},{"key":"ref10","first-page":"617","article-title":"Adverse effects of antipsychotic medications","volume":"81","author":"J Muench","year":"2010","journal-title":"Am Fam Physician"},{"key":"ref11","first-page":"8","article-title":"Antipsychotic medications: metabolic and cardiovascular risk","volume":"68","author":"JW Newcomer","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00023210-200721110-00004","article-title":"Adverse effects of atypical antipsychotics : differential risk and clinical implications","volume":"21","author":"PM Haddad","year":"2007","journal-title":"CNS Drugs"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.4088\/JCP.08r04392","article-title":"Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review","volume":"70","author":"V Simon","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00213-003-1529-4","article-title":"Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses","volume":"170","author":"KI Melkersson","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.psychres.2010.11.021","article-title":"Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with second generation antipsychotics","volume":"189","author":"B Vuksan-Cusa","year":"2011","journal-title":"Psychiatry Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1001\/archpsyc.64.8.966","article-title":"A new brief instrument for assessing decisional capacity for clinical research","volume":"64","author":"DV Jeste","year":"2007","journal-title":"Archives of general psychiatry"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0378-4347(99)00287-X","article-title":"Monitoring of olanzapine in serum by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry","volume":"732","author":"MJ Bogusz","year":"1999","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jpba.2004.01.005","article-title":"A study of matrix effects on an LC\/MS\/MS assay for olanzapine and desmethyl olanzapine","volume":"35","author":"C Chin","year":"2004","journal-title":"J Pharm Biomed Anal"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jpba.2010.03.040","article-title":"Liquid chromatography\/tandem mass spectrometry method for determination of olanzapine and N-desmethylolanzapine in human serum and cerebrospinal fluid","volume":"53","author":"M Josefsson","year":"2010","journal-title":"J Pharm Biomed Anal"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0378-4347(00)00438-2","article-title":"A sensitive high-performance liquid chromatographic method using electrochemical detection for the analysis of olanzapine and desmethylolanzapine in plasma of schizophrenic patients using a new solid-phase extraction procedure.","volume":"750","author":"MA Raggi","year":"2001","journal-title":"Journal of Chromatography B: Biomedical Sciences and Applications"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF02492246","article-title":"Determination of Olanzapine and Desmethylolanzapine in the Plasma of Schizophrenic Patients by Means of an Improved HPLC Method with Amperometric Detection.","volume":"54","author":"MA Raggi","year":"2001","journal-title":"Chromatographia"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0378-4347(95)00061-M","article-title":"Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection","volume":"668","author":"JT Catlow","year":"1995","journal-title":"J Chromatogr B Biomed Appl"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/FTD.0b013e31815bde43","article-title":"Simultaneous high-performance liquid chromatographic determination of olanzapine and lamotrigine in plasma of bipolar patients","volume":"29","author":"MA Saracino","year":"2007","journal-title":"Ther Drug Monit"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.chroma.2006.04.011","article-title":"Determination of Olanzapine in rat brain using liquid chromatography with coulometric detection and a rapid solid-phase extraction procedure.","volume":"1122","author":"MA Saracino","year":"2006","journal-title":"Journal of Chromatographic Science"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.aca.2004.04.031","article-title":"Rapid analysis of olanzapine and desmethylolanzapine in human plasma using high-performance liquid chromatography with coulometric detection","volume":"516","author":"C Sabbioni","year":"2004","journal-title":"Analytica chimica acta"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0731-7085(95)01651-1","article-title":"Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection.","volume":"14","author":"JA Chiu","year":"1996","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1055\/s-2004-815527","article-title":"Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients","volume":"37","author":"N Bergemann","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/01.ftd.0000211800.66569.c9","article-title":"Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection","volume":"28","author":"C D'Arrigo","year":"2006","journal-title":"Therapeutic Drug Monitoring"},{"key":"ref29","unstructured":"Guidance for Industry. Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug administration. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070107.pdf\" xlink:type=\"simple\">www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070107.pdf<\/ext-link>. Accessed 2013 May 4."},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1214\/aos\/1013699998","article-title":"The control of the false discovery rate in multiple testing under dependency","volume":"29","author":"Y Benjamini","year":"2001","journal-title":"Ann Stat"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/s-2004-832687","article-title":"The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry","volume":"37","author":"P Baumann","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011","volume":"44","author":"C Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2165\/11587240-000000000-00000","article-title":"Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?","volume":"50","author":"E Schwenger","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2165\/11589060-000000000-00000","article-title":"Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder","volume":"31","author":"L Citrome","year":"2011","journal-title":"Clin Drug Investig"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1038\/sj.npp.1301051","article-title":"Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents","volume":"31","author":"I Elman","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/01.jcp.0000237947.80764.d9","article-title":"The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients","volume":"26","author":"CC Chiu","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.pnpbp.2010.04.003","article-title":"The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine","volume":"34","author":"CC Chiu","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1731S","DOI":"10.1093\/jn\/136.6.1731S","article-title":"The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease","volume":"136","author":"H Refsum","year":"2006","journal-title":"J Nutr"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.pnpbp.2005.06.029","article-title":"High homocysteine serum levels in young male schizophrenia and bipolar patients and in an animal model","volume":"29","author":"J Levine","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1097\/00001756-199907130-00008","article-title":"Plasma homocysteine and the methylenetetrahydrofolate reductase C677T gene variant: lack of association with schizophrenia","volume":"10","author":"C Virgos","year":"1999","journal-title":"Neuroreport"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1176\/appi.ajp.159.10.1790","article-title":"Elevated homocysteine levels in young male patients with schizophrenia","volume":"159","author":"J Levine","year":"2002","journal-title":"Am J Psychiatry"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0006-3223(97)00427-7","article-title":"Schizophrenia and impaired homocysteine metabolism: a possible association","volume":"44","author":"E Susser","year":"1998","journal-title":"Biol Psychiatry"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/01.wnr.0000215777.99473.52","article-title":"Serum homocysteine, folate level and methylenetetrahydrofolate reductase 677, 1298 gene polymorphism in Korean schizophrenic patients","volume":"17","author":"YS Lee","year":"2006","journal-title":"Neuroreport"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4306\/pi.2011.8.2.134","article-title":"Serum homocysteine and folate levels in korean schizophrenic patients","volume":"8","author":"TH Kim","year":"2011","journal-title":"Psychiatry Investig"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.pnpbp.2005.06.027","article-title":"Homocysteinemia as well as methylenetetrahydrofolate reductase polymorphism are associated with affective psychoses","volume":"29","author":"A Reif","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0021-9150(01)00442-7","article-title":"The effect of glucose and insulin on the activity of methylene tetrahydrofolate reductase and cystathionine-beta-synthase: studies in hepatocytes","volume":"158","author":"A Dicker-Brown","year":"2001","journal-title":"Atherosclerosis"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1600-0447.2005.00621.x","article-title":"Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia","volume":"113","author":"DC Henderson","year":"2006","journal-title":"Acta Psychiatr Scand"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00228-009-0783-8","article-title":"Carriers of the UGT1A4 142T&gt;G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients","volume":"66","author":"R Ghotbi","year":"2010","journal-title":"European journal of clinical pharmacology"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/FTD.0b013e31816336fd","article-title":"The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP)","volume":"30","author":"M Nozawa","year":"2008","journal-title":"Therapeutic drug monitoring"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/tpj.2009.32","article-title":"Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome","volume":"10","author":"B Laika","year":"2010","journal-title":"The pharmacogenomics journal"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0065719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T15:14:58Z","timestamp":1645629298000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0065719"}},"subtitle":[],"editor":[{"given":"Kenji","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,5,31]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,5,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0065719","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,31]]}}}